Emerging evidence suggests that a high burden of copy number loss is correlated with resistance to anti-PD-1 and anti-CTLA-4 therapies, indicating that copy number loss is closely linked to tumor immune evasion 46. This evidence concerns the gene CTLA4 and neoplasm.